Teva launches generic Restasis in Canada

Teva Canada Limited announced the launch of a twice-daily eye drop solution — the first generic version of Allergan’s Restasis in Canada.
May 18, 2018

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries, announced the launch of a twice-daily eye drop solution — the first generic version of Allergan’s Restasis in Canada.

Teva-Cyclosporine is available immediately to pharmacies across Canada.

In the U.S., Allergan is still locked in patent battles with Mylan and Teva over Restasis, but Teva's Canada launch could put pressure on the U.S. court system and the FDA to push a generic version of the drug.

Read the press release

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates